<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02513121</url>
  </required_header>
  <id_info>
    <org_study_id>2015-4405</org_study_id>
    <nct_id>NCT02513121</nct_id>
  </id_info>
  <brief_title>Dietary Treatment Study of Pediatric NAFLD</brief_title>
  <acronym>DTS</acronym>
  <official_title>Randomized, Controlled Dietary Treatment Study of Pediatric NAFLD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nutrition Science Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigator initiated study being conducted in equal numbers at two sites, UC San
      Diego and Emory University. The purpose of this study is to understand the potential of a low
      sugar diet for the treatment of nonalcoholic fatty liver disease (NAFLD) in children. Forty
      boys with NAFLD will be randomly assigned to either an intervention group or a habitual diet
      control group. The intervention will be a low sugar diet for a period of 8 weeks. The effect
      of this dietary change will be assessed using advanced MRI testing to measure liver fat.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">August 31, 2017</completion_date>
  <primary_completion_date type="Actual">August 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of fat in the liver measured by proton density fat fraction (PDFF)</measure>
    <time_frame>Eight (8) weeks</time_frame>
    <description>To evaluate change in liver fat over 8 weeks in response to a low sugar diet in children with NAFLD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in alanine aminotransferase (ALT)</measure>
    <time_frame>Eight (8) weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in aspartate aminotransferase (AST)</measure>
    <time_frame>Eight (8) weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gamma-glutamyl transferase (GGT)</measure>
    <time_frame>Eight (8) weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>Eight (8) weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body mass index (BMI)</measure>
    <time_frame>Eight (8) weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>Eight (8) weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Dietary modification</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low free sugar diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dietary modification</intervention_name>
    <description>The intervention is a modification of the family's habitual diet with a low sugar version of their diet.</description>
    <arm_group_label>Dietary modification</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Boys age 11-16 years inclusive.

          -  Clinical history consistent with NAFLD.

          -  Biopsy-proven NAFLD

          -  MRI measured Liver Proton Density Fat Fraction ≥10%

          -  ALT ≥ 45 u/L

          -  No evidence of any other liver disease by clinical history or histological evaluation.

          -  Written informed consent from parent or legal guardian.

          -  Written informed assent from the child or adolescent.

        Exclusion Criteria:

        Exclusions will not be based upon gender, race, or ethnicity. Participants with a current
        history of the following conditions or any other health issues that make it unsafe for them
        to participate in the opinion of the Investigators will be excluded from the study:

          -  History of significant alcohol intake (AUDIT questionnaire) or inability to quantify
             alcohol consumption

          -  Chronic use (more than 2 consecutive weeks) of medications known to cause hepatic
             steatosis or steatohepatitis in the past year.

          -  The use of other known hepatotoxins within 120 days of baseline

          -  History of total parenteral nutrition (TPN) use in the year prior to screening

          -  History of bariatric surgery or planning to undergo bariatric surgery during the study
             duration

          -  Significant depression

          -  Non-compensated liver disease with any one of the following hematologic, biochemical,
             and serological criteria on entry into protocol:

          -  Hemoglobin &lt; 10 g/dL

          -  White blood cell &lt; 3,500 cells/mm

          -  Neutrophil count &lt; 1,500 cells/mm3 of blood

          -  Platelets &lt; 130,000 cells/mm3 of blood

          -  Direct bilirubin &gt; 1.0 mg/dL

          -  Total bilirubin &gt; 3 mg/dL

          -  Albumin &lt; 3.2 g/dL

          -  International normalized ratio (INR) &gt; 1.4

          -  Evidence of other chronic liver disease

          -  Children who are currently enrolled in a clinical trial or who received an
             investigational study drug or a medication with the intent to treat NAFLD/NASH in the
             past 60 days

          -  Contraindications to MRI, e.g. metal in the eyes, implanted electronic devices,
             aneurysm clips, pacemaker, cochlear implants

          -  Unable to have or complete the MRI exam due to body weight exceeding scanner table
             limit or girth exceeding scanner bore diameter

          -  Subjects who are not able or willing to comply with the protocol or have any other
             condition that would impede compliance or hinder completion of the study, in the
             opinion of the investigator

          -  Families with &gt; 5 individuals

          -  Failure to give informed consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey B Schwimmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miriam Vos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr. 2003 Oct;143(4):500-5.</citation>
    <PMID>14571229</PMID>
  </reference>
  <reference>
    <citation>Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006 Oct;118(4):1388-93.</citation>
    <PMID>17015527</PMID>
  </reference>
  <reference>
    <citation>Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation. 2008 Jul 15;118(3):277-83. doi: 10.1161/CIRCULATIONAHA.107.739920. Epub 2008 Jun 30.</citation>
    <PMID>18591439</PMID>
  </reference>
  <reference>
    <citation>Jin R, Le NA, Liu S, Farkas Epperson M, Ziegler TR, Welsh JA, Jones DP, McClain CJ, Vos MB. Children with NAFLD are more sensitive to the adverse metabolic effects of fructose beverages than children without NAFLD. J Clin Endocrinol Metab. 2012 Jul;97(7):E1088-98. doi: 10.1210/jc.2012-1370. Epub 2012 Apr 27.</citation>
    <PMID>22544914</PMID>
  </reference>
  <reference>
    <citation>Jin R, Welsh JA, Le NA, Holzberg J, Sharma P, Martin DR, Vos MB. Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. Nutrients. 2014 Aug 8;6(8):3187-201. doi: 10.3390/nu6083187.</citation>
    <PMID>25111123</PMID>
  </reference>
  <reference>
    <citation>Schwimmer JB, Middleton MS, Behling C, Newton KP, Awai HI, Paiz MN, Lam J, Hooker JC, Hamilton G, Fontanesi J, Sirlin CB. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology. 2015 Jun;61(6):1887-95. doi: 10.1002/hep.27666. Epub 2015 Feb 5.</citation>
    <PMID>25529941</PMID>
  </reference>
  <reference>
    <citation>Jin R, Vos MB. Fructose and liver function--is this behind nonalcoholic liver disease? Curr Opin Clin Nutr Metab Care. 2015 Sep;18(5):490-5. doi: 10.1097/MCO.0000000000000203. Review.</citation>
    <PMID>26203597</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2015</study_first_submitted>
  <study_first_submitted_qc>July 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2015</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Jeffrey B. Schwimmer, MD</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>NAFLD</keyword>
  <keyword>Steatohepatitis</keyword>
  <keyword>NASH</keyword>
  <keyword>Liver</keyword>
  <keyword>Diet</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Adolescent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

